Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2008

View Archived Issues

New therapeutic approach against toxoplasmosis reported

MicroRNA mimics suppress Bcr-Abl expression in vitro and in vivo

Phase II trial of Hsp90 inhibitor alvespimycin begins in HER2+ metastatic breast cancer

Data support therapeutic role for buprenorphine in neuropathic pain

Allon initiates phase I clinical trial of AL-108 and AL-208

Three Rivers acquires hepatitis C drug Infergen from Valeant

Vasopressin V2 receptor agonists prepared and tested at Kissei

Roche responds to the results of the IDEAL hepatitis C trial reported

Upstream enters agreement with MSU for drug candidates for tropical parasitic diseases

FDA grants approval to DAKO to market the TOP2A FISH pharmDx breast-cancer test

Gabriel Sciences receives grant from NIH for development of lead antidepressant compound

Alfacell licenses U.S. commercial rights to Onconase to Strativa Pharmaceuticals

Taranabant induces weight loss in obese subjects

Novartis Pharma and Mitsubishi Tanabe revise agreement for Lochol for hypercholesteremia

Genzyme enters license agreement with Moffitt Cancer Center for lung cancer diagnostic

Tolerx receives payment from Genentech following phase Ib clinical study of TRX-1

Anthera reports positive preliminary results from phase IIb clinical trial of A-002

Celsion to proceed with phase II pivotal breast cancer trial

Protox Therapeutics commences phase IIa PRX-302 trial in prostate cancer

Summit's lead drug candidate, SMT-D001, enters phase II clinical trials

Recent patents describe novel analgesic agents

Remicade label enhancement receives E.U. approval in Crohn's disease

E.U. marketing authorization granted for GSK's Avamys for allergic rhinitis therapy

E.C. grants Remicade label enhancement for ankylosing spondylitis and psoriatic arthritis

New oncolytic drugs described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...